Featured Research

from universities, journals, and other organizations

International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports

Date:
August 26, 1998
Source:
Bowman Gray/Baptist Hospital Medical Center
Summary:
A new international study shows a class of drugs known as statins raises levels of the good cholesterol, John R. Crouse III, M.D., reported in a presentation today (Aug. 24) to the European Society of Cardiology in Vienna.

A new international study shows a class of drugs known as statins raises levels of the good cholesterol, John R. Crouse III, M.D., reported in a presentation today (Aug. 24) to the European Society of Cardiology in Vienna.

Crouse, professor of internal medicine (endocrinology/metabolism) and director of the Preventive Cardiology Program at the Wake Forest University Baptist Medical Center, said the study, together with other information presented at the meeting, re-emphasizes the importance of the so-called good cholesterol, high-density lipoprotein (HDL) cholesterol.

"These results suggest that HDL may have a greater import than we have given it," said Crouse, noting the emphasis in recent years on low density lipoprotein (LDL) and triglycerides.

The study involved 842 patients at 49 centers in 19 countries and compared two doses of two statin drugs -- simvastatin and atorvastatin. Both drugs raised HDL, particularly in patients who had an HDL cholesterol below 35 -- which National Cholesterol Education Program classifies as a "major risk factor for coronary heart disease." The effect was more dramatic for simvastatin.

Depending on the drug and the dose, the increase in HDL in patients who started the study with an HDL below 35 ranged from about 7 percent on the higher dose of atorvastatin to 18 percent on the higher dose of simvastatin. The HDL-raising effects of the lower doses of both drugs were in between.

In patients whose HDL cholesterol was above 35, the increases were less dramatic, with simvastatin doing about twice as well as atorvastatin at both doses.

According to the National Cholesterol Education Program, the higher the HDL, the better, and HDL above 60 appears to be protective against heart disease.

"We did not expect to see such dramatic effects of a statin on low HDL, nor did we expect to find that there was a differential effect between simvastatin and atorvastatin," Crouse said.

Patients in the study got one of four treatments: 40 milligrams or 80 milligrams of simvastatin (Zocor, manufactured by Merck & Co., Inc.). or 20 milligrams or 40 milligrams of atorvastatin (Lipitor, manufactured by the Parke Davis division of Warner-Lambert Co., and marketed both by Parke Davis and Pfizer Inc.) Patients took the assigned drug once each evening for 12 weeks.

Crouse and his colleagues also separately analyzed male and female patients and found that in women, the higher dose of simvastatin was significantly better than the higher dose of atorvastatin in raising HDL, but at the lower doses, the two drugs were equivalent.

Among men, the simvastatin was significantly better than the atorvastatin in raising HDL at both doses.

The study also looked at low-density lipoprotein (LDL) cholesterol and found both drugs substantially reduced LDL, regardless of dose. Both drugs also reduced triglycerides to a similar extent. (The lower the LDL, the lower the risk of coronary heart disease, according to the National Cholesterol Education Program, a national coalition of medical groups.)

"The observation that simvastatin beneficially raises low HDL while lowering LDL should make this finding attractive to physicians for the lipid-altering properties that collectively lower cardiovascular risk," Crouse said.

All patients were put on a low-fat diet four weeks before the drug trial began.

"It has not yet been established that increasing HDL cholesterol by itself reduces the risk of coronary events," Crouse said, but statistics show that as HDL goes up, the incidence of coronary heart disease decreases.

Other studies have shown that each point (milligram per deciliter) increase in HDL corresponds to a 2 to 3 percent reduction in the risk of developing coronary artery disease.

Crouse added, "If HDL is important, then factors that raise HDL may be important."

According to industry sources, the cholesterol-lowering market is now valued at $7.5 billion annually.


Story Source:

The above story is based on materials provided by Bowman Gray/Baptist Hospital Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Bowman Gray/Baptist Hospital Medical Center. "International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports." ScienceDaily. ScienceDaily, 26 August 1998. <www.sciencedaily.com/releases/1998/08/980826082434.htm>.
Bowman Gray/Baptist Hospital Medical Center. (1998, August 26). International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/1998/08/980826082434.htm
Bowman Gray/Baptist Hospital Medical Center. "International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports." ScienceDaily. www.sciencedaily.com/releases/1998/08/980826082434.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins